U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Medical Devices
  3. Medical Device Safety
  4. Letters to Health Care Providers
  5. Update: Potential Risk of Exposure to Toxic Compounds When Using Hemodialysis and Peritoneal Dialysis Systems – Letter to Health Care Providers
  1. Letters to Health Care Providers

Update: Potential Risk of Exposure to Toxic Compounds When Using Hemodialysis and Peritoneal Dialysis Systems – Letter to Health Care Providers

Update: December 5, 2024 

The FDA is updating this communication to provide information about two additional recalls related to this issue. 

  • Baxter is correcting its MiniCap Extended Life PD Transfer Sets based on recent recalls by other manufacturers related to the potential risk of exposure to non-dioxin-like (NDL) polychlorinated biphenyl acids (PCBAs) and NDL polychlorinated biphenyls (PCBs) when using certain peritoneal dialysis and hemodialysis devices. Baxter is in the process of evaluating whether the source of PCBAs and/or NDL PCBs in those recalls (the silicone tubing manufacturing process using a chlorinated peroxide initiator) is present in MiniCap Extended Life PD Transfer Sets. The company is also transitioning certain components in the sets from peroxide-cured silicone tubing to platinum-cured silicone tubing. NDL PCBAs and NDL PCBs are not detected in medical devices with this modified version of silicone tubing.
  • Baxter is correcting its AK 98 dialysis machines based on recent recalls by other manufacturers related to the potential risk of exposure to non-dioxin-like (NDL) polychlorinated biphenyl acids (PCBAs) and NDL polychlorinated biphenyls (PCBs) when using certain peritoneal dialysis and hemodialysis devices. Baxter is in the process of evaluating whether the source of PCBAs and/or NDL PCBs (the silicone tubing manufacturing process using a chlorinated peroxide initiator) is present in AK 98 dialysis machines. The company is also transitioning certain components in these machines from peroxide-cured silicone tubing to platinum-cured silicone tubing. NDL PCBAs and NDL PCBs are not detected in medical devices with this modified version of silicone tubing.

The FDA has identified these actions as Class I, the most serious type of recall. Health care providers should review the recalls, which includes Unique Device Identifier (UDI) information, for the latest safety information about use of these products.

The FDA’s recommendations have not changed.

March 7, 2023

The U.S. Food and Drug Administration (FDA) is continuing to evaluate the potential risk of exposure to toxic compounds when using dialysis systems. On May 6, 2022, the FDA issued a Letter to Health Care Providers about the evaluation of the potential risk of exposure to non-dioxin-like (NDL) polychlorinated biphenyl acids (PCBAs) and NDL polychlorinated biphenyls (PCBs) when using certain hemodialysis systems manufactured by Fresenius Medical Care. The source of the NDL PCBAs and NDL PCBs was from the silicone tubing used as a part of the hydraulics in the dialysate lines. Specifically, the manufacturing process of the silicone tubing used a chlorinated peroxide initiator that resulted in NDL PCBAs and NDL PCBs. The FDA worked with Fresenius Medical Care which modified the silicone tubing used in their hemodialysis machines to platinum catalyst silicone tubing. Based on information provided by the manufacturer, NDL PCBAs and NDL PCBs were not detected in machines with the modified silicone tubing.

As a part of the FDA’s ongoing evaluation and work with other manufacturers of hemodialysis and peritoneal dialysis systems, the FDA is aware of other hemodialysis and peritoneal dialysis systems that have parts made of chlorinated peroxide cured silicone but we do not know at this time whether there is any risk of exposure to NDL PCBAs or NDL PCBs. The FDA is working with these manufacturers to further collect and evaluate data to determine the risk of exposure to NDL PCBAs and NDL PCBs on patients and develop strategies to address the issue, if needed. More testing and analysis are needed to determine if NDL PCBAs or NDL PCBs are present in the systems, and if so, the amount and extent of exposure to patients of these toxic compounds. The FDA will provide an update when new information becomes available.

Recommendations

The FDA recognizes that hemodialysis and peritoneal dialysis systems are critical to patient care. 

Health care providers should:

  • Continue to provide dialysis treatments to your patients. 
  • Be aware the FDA is working with manufacturers to understand the potential risk of exposure to NDL PCBAs and NDL PCBs with hemodialysis and peritoneal dialysis systems and develop mitigation strategies, if needed. 
  • Remain alert for further updates and recommendations from the FDA and applicable manufacturers.
  • Report any concerns with hemodialysis or peritoneal dialysis systems to the FDA, including any adverse effects on patients that may be related to the potential exposure to NDL PCBAs or NDL PCBs. 

Background 

Hemodialysis and peritoneal dialysis are used to treat patients who develop serious kidney injury or end-stage kidney disease. In hemodialysis, needles are placed in a patient’s arm to use a machine that pumps blood through a filter outside the body to remove waste and extra fluid, then returns the blood to the body. In peritoneal dialysis, a surgeon places a tube in a patient’s abdomen so dialysis fluid can flow into the belly through the peritoneal membrane (lining of the abdomen) which filters blood inside the body. 

NDL PCBs are a subgroup of polychlorinated hydrocarbon (compounds containing chlorine, carbon, and hydrogen) chemicals. NDL PCBAs are an acid of NDL PCBs. PCBs, including NDL PCBs, are in the environment (such as in soil or wastewater) and pose a risk of harm to humans and animals. NDL PCBs are a byproduct from polymeric material manufacturing where a chlorinated benzoyl peroxide is used as an initiator in the polymerization of the resin. Adverse effects of NDL PCBs in animals have been reported in the literature, such as endocrine dysfunction, hepatic effects, neurobehavioral alterations, and male reproductive effects. 

A source of NDL PCBAs and NDL PCBs in silicone tubing and parts can be the manufacturing process of the silicone that uses a chlorinated peroxide initiator and may result in the generation of NDL PCBAs and NDL PCBs.

FDA Actions (as of December 5, 2024)

In November 2024, the FDA determined the actions by: 

  • Baxter to correct its MiniCap Extended Life PD Transfer Sets based on recent recalls by other manufacturers related to the potential risk of exposure to non-dioxin-like (NDL) polychlorinated biphenyl acids (PCBAs) and NDL polychlorinated biphenyls (PCBs) when using certain peritoneal dialysis and hemodialysis devices as a Class I recall. This recall is a correction, not a product removal. 
  • Baxter to correct its AK 98 dialysis machines based on recent recalls by other manufacturers related to the potential risk of exposure to non-dioxin-like (NDL) polychlorinated biphenyl acids (PCBAs) and NDL polychlorinated biphenyls (PCBs) when using certain peritoneal dialysis and hemodialysis devices as a Class 1 recall. This recall is a correction, not a product removal.  

On April 25, 2024, the FDA determined the actions by:

  • Outset Medical Inc. to address NDL-PCBAs with Tablo Hemodialysis Systems as a Class I recall, the most serious type of recall. This recall is a correction, not a product removal.
  • Fresenius Medical Care to address NDL-PCBAs with the stay-safe catheter extension sets and luer lock adaptors used with peritoneal dialysis machines as a Class I recall, the most serious type of recall. This recall is a correction, not a product removal.

On October 06, 2023, the FDA determined the actions by Fresenius Medical Care to update affected 2008 Series Hemodialysis machines from chlorinated peroxide cured silicone tubing to platinum cured silicone tubing as a Class I recall, the most serious type of recall. This recall is a correction, not a product removal.

The FDA continues working with manufacturers of hemodialysis and peritoneal dialysis systems to further collect and evaluate data to determine if NDL PCBAs or NDL PCBs are present in their system, and if so, the amount and extent of exposure to patients, as well as strategies to address the issue if needed. 

In addition, the FDA continues to work with industry and external stakeholders to better understand the potential risks of using a chlorinated peroxide initiator for silicone as part of the manufacturing process by different device types. 

The FDA will inform the public when significant new information or recommendations become available.

Reporting Problems to the FDA 

The FDA encourages health care providers to report any adverse events or suspected adverse events experienced with medical devices. Prompt reporting can help the FDA identify and better understand the risks associated with medical devices and improve patient safety.

Contact Information 

If you have questions about this letter, contact the Division of Industry and Consumer Education (DICE).

Additional Resources 

Back to Top